As of September 2023 it is on the FDA's Category 2 list of bulk drug substances that may not be compounded due to significant safety risks, and the agency has scheduled a Pharmacy Compounding Advisory Committee (PCAC) review for July 2026 covering proposed uses in opioid withdrawal, chronic insomnia, and narcolepsy
GLP-1 expenses may be reimbursed when supported by a prescription or letter of medical necessity, depending on plan design
What this means for MEDVi MEDVi continues to offer compounded tirzepatide as of the time of this writing
A good candidate has no history of neuromuscular disease, no previous allergic reactions to Botox or lidocaine (please mention these to us, as we have different options available for patients with allergies), and is not pregnant or breastfeeding
EClinicalMedicine 64 , 102181 (2023)
There is no oral form of this blend that survives digestion, which is another reason the protocol is framed entirely around a small subcutaneous dose